Alice Michie
Research Subjects
Alice Michie has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chisha Sikazwe
PathWest Laboratory Medicine, Hospital Avenue, Nedlands, WA 6009, Australia
2 shared publications - Dominic E. Dwyer
Centre for Infectious Diseases and Microbiology - Public Health, Redbank Road, Westmead Hospital, Westmead, New South Wales 2145, Australia
2 shared publications - Edward Charles Holmes
School of Medical Sciences, The University of Sydney, Sydney, Australia
2 shared publications - Jen Kok
School of Medical Sciences and Sydney Infectious Diseases Institute, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales 2006, Australia
2 shared publications - John-Sebastian Eden
University of Sydney
2 shared publications - Karan Kim
Centre for Virus Research, Westmead Institute for Medical Research, Westmead, NSW 2145, Australia
2 shared publications
Latest Publications
- Open Access
- 13 March 2024
- Published by CSIRO Publishing in Microbiology Australia
- Vol. 45 (1) , 8-12
Wastewater-based SARS-CoV-2 surveillance and sequencing
Though most often associated with poliovirus surveillance, wastewater-based surveillance (WBS) can be employed for viruses shed in human excreta (faeces, urine, skin, sputum, blood) that may enter the wastewater system, including SARS-CoV-2. WBS has been widely adopted during the COVID-19 pandemic, to complement clinical surveillance in monitoring community burden and implementing timely public health interventions. As wastewater is a non-biased, composite sample, it can provide population-level health information in near real-time, in a cost-effective manner compared to similarly scaled clinical surveillance. In many instances, data gathered from wastewater, including viral loads (quantified by RT-qPCR) and variant detections (determined through partial or whole genome sequencing), have been predictive of what is observed eventually in clinical cases. Newly emergent lineages, including the recent BA.2.86 variant, can and have been detected in wastewater samples prior to their detection in clinical specimens. There remain many challenges to wastewater genomic analysis including the presence of RT-qPCR inhibitors, degraded nucleic acid and the lack of consistent or standardised methodology between reporting labs. The wide adoption of WBS practices provides an excellent opportunity to expand this method for surveillance of other pathogens of public health importance. Herein, a broad overview of the WBS field will be provided including discussion on its advantages and applications, challenges, and how it is being utilised to characterise circulating SARS-CoV-2 lineages through sequencing.
- 13 March 2024
- Published by CSIRO Publishing in Microbiology Australia
- Vol. 45 (1) , 8-12
Open AccessWastewater-based SARS-CoV-2 surveillance and sequencing
Though most often associated with poliovirus surveillance, wastewater-based surveillance (WBS) can be employed for viruses shed in human excreta (faeces, urine, skin, sputum, blood) that may enter the wastewater system, including SARS-CoV-2. WBS has been widely adopted during the COVID-19 pandemic, to complement clinical surveillance in monitoring community burden and implementing timely public health interventions. As wastewater is a non-biased, composite sample, it can provide population-level health information in near real-time, in a cost-effective manner compared to similarly scaled clinical surveillance. In many instances, data gathered from wastewater, including viral loads (quantified by RT-qPCR) and variant detections (determined through partial or whole genome sequencing), have been predictive of what is observed eventually in clinical cases. Newly emergent lineages, including the recent BA.2.86 variant, can and have been detected in wastewater samples prior to their detection in clinical specimens. There remain many challenges to wastewater genomic analysis including the presence of RT-qPCR inhibitors, degraded nucleic acid and the lack of consistent or standardised methodology between reporting labs. The wide adoption of WBS practices provides an excellent opportunity to expand this method for surveillance of other pathogens of public health importance. Herein, a broad overview of the WBS field will be provided including discussion on its advantages and applications, challenges, and how it is being utilised to characterise circulating SARS-CoV-2 lineages through sequencing.
- Open Access
RAPIDprep: A Simple, Fast Protocol for RNA Metagenomic Sequencing of Clinical Samples
Emerging infectious disease threats require rapid response tools to inform diagnostics, treatment, and outbreak control. RNA-based metagenomics offers this; however, most approaches are time-consuming and laborious. Here, we present a simple and fast protocol, the RAPIDprep assay, with the aim of providing a cause-agnostic laboratory diagnosis of infection within 24 h of sample collection by sequencing ribosomal RNA-depleted total RNA. The method is based on the synthesis and amplification of double-stranded cDNA followed by short-read sequencing, with minimal handling and clean-up steps to improve processing time. The approach was optimized and applied to a range of clinical respiratory samples to demonstrate diagnostic and quantitative performance. Our results showed robust depletion of both human and microbial rRNA, and library amplification across different sample types, qualities, and extraction kits using a single workflow without input nucleic-acid quantification or quality assessment. Furthermore, we demonstrated the genomic yield of both known and undiagnosed pathogens with complete genomes recovered in most cases to inform molecular epidemiological investigations and vaccine design. The RAPIDprep assay is a simple and effective tool, and representative of an important shift toward the integration of modern genomic techniques with infectious disease investigations.
Open AccessRAPIDprep: A Simple, Fast Protocol for RNA Metagenomic Sequencing of Clinical Samples
Emerging infectious disease threats require rapid response tools to inform diagnostics, treatment, and outbreak control. RNA-based metagenomics offers this; however, most approaches are time-consuming and laborious. Here, we present a simple and fast protocol, the RAPIDprep assay, with the aim of providing a cause-agnostic laboratory diagnosis of infection within 24 h of sample collection by sequencing ribosomal RNA-depleted total RNA. The method is based on the synthesis and amplification of double-stranded cDNA followed by short-read sequencing, with minimal handling and clean-up steps to improve processing time. The approach was optimized and applied to a range of clinical respiratory samples to demonstrate diagnostic and quantitative performance. Our results showed robust depletion of both human and microbial rRNA, and library amplification across different sample types, qualities, and extraction kits using a single workflow without input nucleic-acid quantification or quality assessment. Furthermore, we demonstrated the genomic yield of both known and undiagnosed pathogens with complete genomes recovered in most cases to inform molecular epidemiological investigations and vaccine design. The RAPIDprep assay is a simple and effective tool, and representative of an important shift toward the integration of modern genomic techniques with infectious disease investigations.
- Open Access
- 22 December 2022
- Published by MDPI AG in Preprints.org
RAPIDprep: A Simple, Fast Protocol for RNA Metagenomic Sequencing of Clinical Samples
Emerging infectious disease threats require rapid response tools to inform diagnostics, treatment, and outbreak control. RNA-based metagenomics offers this; however, most approaches are time-consuming and laborious. Here, we present a simple and fast protocol – the RAPIDprep assay – with the aim to provide cause agnostic laboratory diagnosis of infection within 24 hours of sample collection by sequencing ribosomal RNA-depleted total RNA. The method is based on the synthesis and amplification of double-stranded cDNA followed by short-read sequencing with minimal handling and clean-up steps to improve processing time. The approach was optimized and applied to a range of clinical respiratory samples to demonstrate diagnostic and quantitative performance. Our results showed robust depletion of both human and microbial rRNA, and library amplification across different sample types, qualities and extraction kits using a single protocol without input nucleic acid quantification or quality assessment. Furthermore, we demonstrate the genomic yield of both known and undiagnosed pathogens with complete genomes recovered in most cases to inform molecular epidemiological investigations and vaccine design. The RAPIDprep assay is a simple and effective tool, and representative of an important shift towards integration of modern genomic techniques to infectious disease investigations.
- 22 December 2022
- Published by MDPI AG in Preprints.org
Open AccessRAPIDprep: A Simple, Fast Protocol for RNA Metagenomic Sequencing of Clinical Samples
Emerging infectious disease threats require rapid response tools to inform diagnostics, treatment, and outbreak control. RNA-based metagenomics offers this; however, most approaches are time-consuming and laborious. Here, we present a simple and fast protocol – the RAPIDprep assay – with the aim to provide cause agnostic laboratory diagnosis of infection within 24 hours of sample collection by sequencing ribosomal RNA-depleted total RNA. The method is based on the synthesis and amplification of double-stranded cDNA followed by short-read sequencing with minimal handling and clean-up steps to improve processing time. The approach was optimized and applied to a range of clinical respiratory samples to demonstrate diagnostic and quantitative performance. Our results showed robust depletion of both human and microbial rRNA, and library amplification across different sample types, qualities and extraction kits using a single protocol without input nucleic acid quantification or quality assessment. Furthermore, we demonstrate the genomic yield of both known and undiagnosed pathogens with complete genomes recovered in most cases to inform molecular epidemiological investigations and vaccine design. The RAPIDprep assay is a simple and effective tool, and representative of an important shift towards integration of modern genomic techniques to infectious disease investigations.